Colon diseases (Patients undergoing routine total colonoscopy)
Conditions
Interventions
On the day before colonoscopy: 48mg of sennoside once at bedtime. On the day of colonoscopy: 1.2L of polyethylene glycol + ascorbic acid (Moviprep
Ajinomoto Ltd, Tokyo, Japan
composed of 200g of macrogol 4000, electrolytes and 9.400g ascorbic acid) diluted into 2.0L of plain water and at least 0.6L of additional clear fluid.
On the day before colonoscopy: 48mg of sennoside
composed of macrogol 4000 and electrolytes) diluted into 2.0L of plain water.
Sponsors
Takamatsu Red Cross Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with an appropriate indication to colonoscopy.
Exclusion criteria
Exclusion criteria: 1. Patients who have known or suspected bowel obstruction or ileus. 2. Patients who have known or suspected perforation. 3. Patients who have significant gastroparesis or gastric outlet obstruction. 4. Patients with severe chronic renal failure (creatinine clearance <30 mL/minute) and severe congestive heart failure (New York Heart Association [NYHA] class III or IV). 5. Patients with sustained tachyarrhythmia. 6. Patients with uncontrolled hypertension (systolic blood pressure >170 mm Hg, diastolic blood pressure >100mmHg). 7. Patients with toxic colitis or megacolon. 8. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Degree of colon cleansing assessed by Boston Bowel Preparation Scale (BBPS) and an original scoring system. | — |
Secondary
| Measure | Time frame |
|---|---|
| Volume of fluid intake, required time to bowel preparation, result of questionnaire on acceptability and evaluation for safety. | — |
Countries
Japan
Contacts
Public ContactHiroyuki Tamaki
Takamatsu Redcross Hospital Gastroenterology
Outcome results
None listed